Navigation Links
Beckman Coulter Announces the Creation of Beckman Coulter Genomics
Date:8/12/2009

rtnership with each customer through a consistent and personalized approach. Our experienced team has the energy and resolve needed to deliver high-quality results scientists can trust, on time and on budget."

Beckman Coulter Genomics has offices throughout North America and Europe. For more information about Beckman Coulter Genomics and its services please visit: www.beckmangenomics.com, www.agencourt.com and www.cogenics.com. For more information about Beckman Coulter, please visit www.beckmancoulter.com.

Beckman Coulter and the stylized logo are registered trademarks of Beckman Coulter, Inc.

*Trademarks are property of their respective owners.

About Beckman Coulter Genomics

Beckman Coulter Genomics, headquartered in Beverly, Massachusetts, is a leading provider of genomic services and nucleic acid purification products, serving life-science researchers and the pharmaceutical industry throughout the world. The company was created by combining Beckman Coulter's Agencourt Bioscience with the newly acquired Cogenics. By providing technical expertise, combined with personalized service, Beckman Coulter Genomics delivers the highest-quality data, robust analyses and innovative thinking. For more information, visit www.beckmangenomics.com, www.agencourt.com or www.cogenics.com.

About Beckman Coulter

Beckman Coulter, Inc., based in Orange County, California, develops, manufactures and markets products that simplify, automate and innovate complex biomedical tests.
'/>"/>

SOURCE Beckman Coulter Genomics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Upcoming Beckman Coulter Investor Events Second Half of 2009
2. Viles & Beckman, LLC: Stop Your Headache NOT Your Liver
3. Beckman Coulter to Present at the 2009 Goldman Sachs Healthcare Conference
4. Beckman Coulter, Inc. Announces Common Stock Offering
5. Beckman Coulter Pending Acquisition of Olympus Diagnostics Systems Passes Milestone with U.S. Regulatory Approval
6. Beckman Coulter Announces First in Series of Flow Cytometry Product Introductions for 2009
7. Beckman Coulter to Present at Upcoming Healthcare Conferences
8. Beckman Coulter Announces Third Quarter 2008 Results
9. Beckman Coulter to Present at the Morgan Stanley Global Healthcare Unplugged Conference
10. Beckman Coulter Announces First Quarter 2008 Earnings to be Released on Wednesday, April 30, 2008, Before Market Opens
11. Beckman Coulters 4th Quarter and Full Year 2007 Revenue Grows 10.8% and 9.2%, Respectively; 2007 Earnings Per Share Beat Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... China,s Northwest Agricultural and Forestry University in Shaanxi province, ... memorandum of agreement that lays the groundwork for establishing ... China. , The signing ceremony was held in the ... officials of the U.S. Department of Agriculture and China,s ... a landmark event for UC Davis and for our ...
(Date:7/23/2014)... Angeles, CA (PRWEB) July 23, 2014 ... practices delivering Enhanced External Counterpulsation (EECP), is ... who receives EECP therapy at the health center. ... ischemic heart disease. Since receiving ongoing EECP therapy since ... , When Sara Soulati, CEO of Global Cardio Care, ...
(Date:7/23/2014)... Unlocking the secrets to better treating the pernicious disorders ... to a paper from American University,s Center for Behavioral ... treating obesity with therapies aimed at areas of the ... focus on the hippocampus could play a role in ... diseases, therapies and preventive measures often fall short. This ...
(Date:7/23/2014)... HealthDay Reporter WEDNESDAY, July 23, ... an additional side benefit -- it may improve urinary ... The study found that nearly half of women ... to the procedure. After surgery, most of those women ... study researcher Dr. Leslee Subak, professor of obstetrics, gynecology ...
(Date:7/23/2014)... catalog the molecular causes of stomach cancer, scientists, ... four subtypes of tumors based on shared mutations ... classification promises to advance clinical research to develop ... , In a report in Nature , ... said they analyzed 295 samples of gastric (stomach) ...
Breaking Medicine News(10 mins):Health News:Global food safety research agreement signed by China and UC Davis 2Health News:Global food safety research agreement signed by China and UC Davis 3Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:Targeting the brain to treat obesity 2Health News:Targeting the brain to treat obesity 3Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 2Health News:Weight Loss Surgery May Help Ease Urinary Incontinence 3Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3
... in low sunlight areas are more likely to experience ... same environment. Researchers believe that these findings should change ... study shows that across the board vitamin D recommendations ... M.D., M.B.A., clinical instructor in the department of urology ...
... well-known risk factor for heart disease. Researchers at the ... participated in an international study of 200,000 Europeans which ... pressure. The discovery, presented in Nature, is an important ... people worldwide suffer from high blood pressure and are ...
... in areas with low sunlight are up to 3 ... men and should take high levels of Vitamin D supplements, ... of Medicine. "This study shows that the current ... Vitamin D don,t work," said Adam Murphy, M.D., a clinical ...
... Tenn. September 19, 2011) The largest study ever of ... tumors carried extra copies of specific genes linked to cancer ... Hospital investigators. The findings identify possible new targets ... diffuse intrinsic pontine glioma (DIPG). Current survival rates for children ...
... , MONDAY, Sept. 19 (HealthDay News) -- Obese 8- ... than their normal-weight peers, a new study finds. In ... of height and weight, at ages 4 and 5 and ... out questionnaires that assessed children,s mental health and health-related quality ...
... HealthDay Reporter , MONDAY, Sept. 19 (HealthDay News) -- ... treating varicose veins, it appears that recurrence of one ... laser treatment, German researchers report. Varicose veins are ... legs. As many as 35 percent of adults suffer ...
Cached Medicine News:Health News:African-American men living in poor sunlight areas at risk for vitamin D deficiency 2Health News:Genetic factors behind high blood pressure 2Health News:One size doesn't fit all for vitamin D and men 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 2Health News:Key regulatory genes often amplified in aggressive childhood tumor of the brainstem 3Health News:Obese Kids May Face Social, Emotional Woes 2Health News:Obese Kids May Face Social, Emotional Woes 3Health News:Two Varicose Veins Treatments Equally Effective 2Health News:Two Varicose Veins Treatments Equally Effective 3
(Date:7/23/2014)... MEETING, Pa. , July 23, 2014 ... INO) today announced successful results from its ... VGX-3100 in women with biopsy-proven cervical intraepithelial ... (HPV) types 16 or 18. Treatment with ... regression of CIN2/3 to CIN1 or no ...
(Date:7/23/2014)... 23, 2014  Lightlake Therapeutics Inc. ("Lightlake") (OTCQB: ... on its expertise in opioid antagonists, announced today ... application ("IND") with respect to its naloxone-based opioid ... that it has received an additional commitment from ... of the National Institutes of Health ("NIH"), to ...
(Date:7/23/2014)... Calif. , July 23, 2014  Cardica, Inc. (Nasdaq: ... financial results for its fiscal fourth quarter and year ended ... markets close. Cardica,s management will host a conference call at ... provide an update on the company,s business. Conference ... 7, 2014, at 4:30 p.m. Eastern Time via phone, please ...
Breaking Medicine Technology:Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 2Lightlake Therapeutics Inc. Files Investigational New Drug Application For Naloxone Nasal Spray For Reversing Opioid Overdose And Announces A Further Collaboration With The National Institute On Drug Abuse 3Cardica to Announce Fiscal 2014 Fourth Quarter and Full Year Financial Results on Thursday, August 7, 2014 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: